Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials.,Gut and Liver

当前位置： X-MOL 学术 › Gut Liver › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials.
Gut and Liver ( IF 3.4 ) Pub Date : 2021-06-02 , DOI: 10.5009/gnl20321
Jeong Heo ₁ , Yoon Jun Kim ₂ , Jin-Woo Lee ₃ , Ji Hoon Kim ₄ , Young-Suk Lim ₅ , Kwang-Hyub Han ₆ , Sook-Hyang Jeong ₇ , Mong Cho ₈ , Ki Tae Yoon ₈ , Si Hyun Bae ₉ , Eric D Crown ₁₀ , Linda M Fredrick ₁₀ , Negar Niki Alami ₁₀ , Armen Asatryan ₁₀ , Do Hyun Kim ₁₁ , Seung Woon Paik ₁₂ , Youn-Jae Lee ₁₃

Affiliation

Department of Internal Medicine, Pusan National University College of Medicine and Medical Research Institute, Pusan National University Hospital, Busan, Korea.
Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Department of Internal Medicine, Inha University School of Medicine, Incheon, Korea.
Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University College of Medicine, Yangsan, Korea.
Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Abbvie Inc., North Chicago, IL, USA.
AbbVie Korea, Ltd., Korea.
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Department of Internal Medicine, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.

Glecaprevir/pibrentasvir (G/P) is the first pan-genotypic direct-acting antiviral combination therapy approved in Korea. An integrated analysis of five phase II and III trials was conducted to evaluate the efficacy and safety of G/P in Korean patients with chronic hepatitis C virus (HCV) infection.

中文翻译：

Glecaprevir/Pibrentasvir 在韩国慢性丙型肝炎患者中的疗效和安全性：五项 II/III 期试验的汇总分析。

Glecaprevir/pibrentasvir (G/P) 是韩国批准的首个泛基因型直接作用抗病毒联合疗法。对五项 II 期和 III 期试验进行了综合分析，以评估 G/P 在韩国慢性丙型肝炎病毒 (HCV) 感染患者中的疗效和安全性。

更新日期：2021-06-02

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11